Lung tumors may release signals that suppress appetite, NIH study finds
NIH-funded researchers report that lung tumors can send molecular signals that reduce food intake, shedding light on cancer-related appetite loss.
A new study funded by the National Institutes of Health suggests that lung tumors can release molecular signals capable of reducing food intake. The findings add to a growing body of research examining how cancer itself can influence appetite, metabolism, and weight loss in patients.
How the Signals Work
Researchers identified biological messengers produced by tumor tissue that appear to act on pathways controlling hunger and satiety. According to the NIH report, these tumor-derived signals may blunt the normal drive to eat, even when the body requires additional energy to cope with illness.
Why Appetite Loss Matters in Cancer
Unintentional weight loss and reduced food intake are common among people with lung cancer and are linked to poorer outcomes, including:
- Weakened response to treatment
- Greater fatigue and muscle loss
- Lower overall quality of life
Understanding the biological basis of cancer-related anorexia could help clinicians develop supportive therapies that protect patients from harmful weight decline while they undergo treatment.
Broader Research Context
Scientists have been investigating how tumor-driven metabolic changes contribute to cachexia, a syndrome of severe weight and muscle wasting seen in many chronic illnesses. Related work, such as studies on the MIND diet's potential role in reducing dementia risk, highlights how diet and disease mechanisms are increasingly studied in parallel across medical fields.
The NIH team indicated that further research is needed to confirm which specific signals are responsible and whether blocking them could safely restore appetite. If validated, the approach could complement nutritional support strategies already used in cancer care, alongside broader dietary frameworks designed to support healthy weight management.
For now, the study reinforces the idea that appetite changes in cancer patients are not simply a side effect of treatment, but can be driven directly by the biology of the tumor itself.